Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

A Letter from President of BIO

Get in Touch

Editor’s Note: James Greenwood, President and CEO of the Bio Industry Organization emailed this letter about the JOBS Act and a link to an FAQ on the BIO site about the act, which provides regulatory relief and was passed by Congress this past spring.  Below is the text of Greenwood’s letter:

Dear BIO Member:

BIO LogoI am sure you have heard about the recent upswing in biotech public offerings. Since Congress passed the JOBS Act last spring, there have been 42 IPOs in our industry – and counting! BIO was a very strong advocate for the JOBS Act, and the increase in public financing over the past year and a half has shown how public policy can affect the day-to-day operations of emerging companies. The biotech story of capital-intensive research that can lead to life-changing medicines rang true with policymakers, and the recent offerings fueled by the JOBS Act will provide funds that can help speed the delivery of cures and treatments to patients in need.

I want to make sure you are aware of another provision in the JOBS Act that took effect this week. As of September 23, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D, as specified by the law. Rule 506 is a popular capital formation outlet that allows issuers to raise an unlimited amount of capital from accredited investors, and the JOBS Act reforms to the process should further increase its utility.

BIO has prepared an overview of the new opportunities available under Rule 506(c) and the requirements for issuers wishing to take advantage of them. Please click here to access this FAQ document. This member service is a non-legal policy overview of the statute, designed to help keep you informed on the new rules. It is not intended to, and does not, constitute legal advice – please consult your own legal team if you are considering an offering or have any specific questions about the statute or relevant SEC regulations.

BIO is continuing to work in Washington to facilitate capital formation for growing biotechs across the country. We are hopeful that the reforms to Regulation D will support biotech offerings, and we will continue to engage with Congress, the SEC, and the Administration to bolster capital markets access and efficiency for emerging innovators. If you have any general questions about the JOBS Act or Regulation D, feel free to contact Charles Crain on BIO’s staff at [email protected].

BIO President James GreenwoodSincerely,

James C. Greenwood

President and Chief Executive Officer

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E